Portal de Periódicos da CAPES

Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

2021; Elsevier BV; Volume: 138; Issue: 2 Linguagem: Inglês

10.1182/blood.2020010218

1528-0020

Hilary Whitworth, Sarah E. Sartain, Riten Kumar, Katherine Armstrong, Lance Ballester, Marisol Betensky, Clay T. Cohen, Rosa Díaz, Caroline Diorio, Neil A. Goldenberg, Julie Jaffray, Jacquelyn Keegan, Kendra Malone, Adrienne G. Randolph, Stacey Rifkin-Zenenberg, W. Leung, Anthony A. Sochet, Lakshmi Srivaths, Ayesha Zia, Leslie Raffini,

Coronary Artery Anomalies

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombotic complications in adults, but the incidence of COVID-19-related thrombosis in children and adolescents is unclear. Most children with acute COVID-19 have mild disease, but coagulopathy has been associated with multisystem inflammatory syndrome in children (MIS-C), a postinfectious complication. We conducted a multicenter retrospective cohort study to determine the incidence of thrombosis in children hospitalized with COVID-19 or MIS-C and evaluate associated risk factors. We classified patients into 1 of 3 groups for analysis: COVID-19, MIS-C, or asymptomatic SARS-CoV-2. Among a total of 853 admissions (COVID-19, n = 426; MIS-C, n = 138; and asymptomatic SARS-CoV-2, n = 289) in 814 patients, there were 20 patients with thrombotic events (TEs; including 1 stroke). Patients with MIS-C had the highest incidence (9 [6.5%] of 138) vs COVID-19 (9 [2.1%] of 426) or asymptomatic SARS-CoV-2 (2 [0.7%] of 289). In patients with COVID-19 or MIS-C, a majority of TEs (89%) occurred in patients age ≥12 years. Patients age ≥12 years with MIS-C had the highest rate of thrombosis at 19% (9 of 48). Notably, 71% of TEs that were not present on admission occurred despite thromboprophylaxis. Multivariable analysis identified the following as significantly associated with thrombosis: age ≥12 years, cancer, presence of a central venous catheter, and MIS-C. In patients with COVID-19 or MIS-C, hospital mortality was 2.3% (13 of 564), but it was 28% (5 of 18) in patients with TEs. Our findings may help inform pediatric thromboprophylaxis strategies.